Is the FDA Jamming the Biotechnology Pipeline?

What does the recent decline in Food and Drug Administration approvals for biopharmaceutical products mean for the industry? Pharma industry communications specialist Mark Senak looks at the future of biotechnology and how product-to-market delays will affect physicians, patients, and investors.

Posted on March 19th, 2008 | More Analysts & Investors · Healthcare

Facebook 2.IPO: Why Communicators Should Watch

While Facebook prepares to go public, communicators appear to be in for a huge learning experience. In a PRWeek article, International Advisory Board member John Onoda weighs in — and suggests we’ll see “a new chapter of PR unfold.”

Read: Facebook From the 50-Yard Line

Posted on February 8th, 2012 | More Analysts & Investors · Digital & Social Media · Financial Communications
The Role of Digital Communications and ‘Pharmacovigilance’

In an article in PharmaVoice, pharma specialist Mark Senak discusses pharmacovigilance communication and explains why the best digital strategy includes “the concept of a two-way exchange.”

Read: Best Practices in Pharmacovigilance

Posted on February 3rd, 2012 | More Crisis Communications · Digital & Social Media · Healthcare
The E-Doctor Will See You Now

Will the cloud help when you’re under the weather? Pharma specialist Mark Senak looks at how technology has changed the patient experience, suggesting physicians might not realize “the change it demands.”

Posted on January 26th, 2012 | More Digital & Social Media · Healthcare · Mobile · Public Affairs · Technology